| 51st week of 2008 patent applcation highlights part 36 |
| Patent application number | Title | Published |
|---|
| 20080311054 | Compositions and Methods to Counteract Oral Malodour - The invention relates to hedonistically pleasing oral malodour counteracting compositions including flavour compositions and oral care products, methods to form such compositions and methods to counteract oral malodour. The compositions comprises 2 or more of oral malodour counteracting actives of formula I in a total concentration of at least 10% (w/w) based on the total concentration of flavour ingredients, and an individual concentration of 1% or more per oral malodour counteractant, based on total flavour ingredients. The maximum concentration of any individual oral malodour counteracting active based on the total of oral malodour counteracting actives is 70%. The identified oral malodour counteracting actives are various flavour compounds and natural ingredients. | 2008-12-18 |
| 20080311055 | MONO-, DI- AND POLYOL ALKOXYLATE PHOSPHATE ESTERS IN ORAL CARE FORMULATIONS AND METHODS FOR USING SAME - This invention relates to a composition useful as an oral care composition comprising an organophosphate material, additional oral care composition ingredients, for example, a surfactant agent, and optionally an abrasive agent. | 2008-12-18 |
| 20080311056 | Bactericide Against Streptococcus Mutans and Streptococcus Sobrinus - The present invention provides an enzyme with lytic activity against cariogenic bacteria and a means for treating and preventing tooth decay using the enzyme. The enzyme provided by the present invention is a lytic enzyme produced by | 2008-12-18 |
| 20080311057 | Bleaching Toothpastes and Methods for Making and Using Them - In toothpaste, the addition of the Iodide ion by way of iodide salts, such as sodium iodide and potassium iodide, to a peroxide such as hydrogen peroxide in a basic medium yields free radical oxygen and water; generating large amounts of heat and depleting the Hydrogen Peroxide in a matter of minutes. The free radical oxygen generated in this reaction can be utilized to oxidize organic molecules that produce offending stains on select items, including artificial teeth and other dental appliances. Once the free radical oxygen has oxidized the offending molecule the color is lost and the solubility changes allowing any loose fragments of the offending molecule to be washed away in the solvent. The iodide ion catalyzes the reaction allowing for precise control over the speed at which the stain is removed without the need for other expensive, cumbersome energy adding equipment such as lights, lasers, heat sources, etc. | 2008-12-18 |
| 20080311058 | Stable high internal phase emulsions and compositions comprising the same - High internal phase emulsions and end use compositions made therefrom are described. The high internal phase emulsions have superior stability and sensory characteristics and can be prepared with less than 20% by weight elastomer, an emulsifier and a steric stabilizer characterized as a polyether and/or polyglycerine cross-linked elastomer. | 2008-12-18 |
| 20080311059 | COMPOSITION FOR SKIN CARE AND METHOD FOR THE SAME - A skin whitening composition and a method for the same are provided. The skin whitening composition comprises a far-infrared ray releasing substance having a primary component of an oxide mineral, wherein the skin whitening composition achieves a whitening effect via an irradiation of the far-infrared ray releasing substance. In another aspect, the method comprises the steps of administering a far-infrared ray releasing substance to a subject and reducing melanogenesis of the subject by inhibiting growth of a pigment cell, wherein the far-infrared releasing substance has an oxide mineral. | 2008-12-18 |
| 20080311060 | Organopolysiloxane, a method of preparing the same and a cosmetic comprising the same - An organopolysiloxane having a main chain composed of the following repeating units (I), 2 to 199 side chain units (II) and 1 to 50 crosslinkage units (III) per 100 SiO units in the main chain, provided that the organopolysiloxane has at least 2, on average, crosslinkage units (III): | 2008-12-18 |
| 20080311061 | Cosmetic Skin Color Determination and Color Mixing Apparatus - A cosmetic color apparatus includes a color measurement device for measuring a skin color of an individual. A computer processing device is provided in communication the color measurement device for performing a comparison of the measured skin color with a desired color so as to provide color information. A color mixing device is provided in communication with the computer processing device for mixing a plurality of pigments based on the color information so as to provide a cosmetic color mixture. | 2008-12-18 |
| 20080311062 | Water-In-Oil Emulsions For Hair Treatment - The present invention provides a water-in-oil emulsion for hair treatment comprising: (a) an oil phase comprising: (i) a first oily component which is one or more glyceride fatty esters, and (ii) a second oily component which is one or more hydrocarbon oils of average carbon chain length less than 20 carbon atoms; (b) a hydrophilic phase comprising: (i) water, (ii) a nonionic emulsifier which is an ethoxylated alcohol having an HLB of at least 6, and (c) dispersed particles of a hair treatment wax. | 2008-12-18 |
| 20080311063 | Method for Imparting Curl to Lashes - There is a method for imparting curl to eyelashes. The method has the step of applying to the eyelashes an anhydrous liquid composition having the following: a) an organic solvent and b) an alkyl cycloalkylacrylate copolymer soluble or dispersible in the solvent. The organic solvent is present in an amount sufficient to dissolve or disperse the alkyl cycloalkylacrylate copolymer. The alkyl cycloalkylacrylate copolymer is present at about 0.1 wt % to about 90 wt % based on the total weight of the composition. | 2008-12-18 |
| 20080311064 | Higher Performance Capsule Particles - It is an object of our invention to provide capsule particles and a method of creating larger and robust capsule particles that will have excellent storage stability and enhanced perfumer performance in a range of consumer products. | 2008-12-18 |
| 20080311065 | Anti-oxidant macromonomers and polymers and methods of making and using the same - The present invention relates to macromonomer compounds possessing antioxidant properties, antioxidant polymers comprising the antioxidant macromonomers as a recurring unit, and methods of inhibiting oxidation in a substance comprising contacting the substance with the antioxidant polymers. In one embodiment, substantially all of the recurring macromonomeric units of the antioxidant polymers comprise an antioxidant moiety. In another embodiment, all of the recurring macromonomer units of the antioxidant polymers comprise an antioxidant moiety. The method of the present invention, yields antioxidant polymers with substantially all of the recurring units comprising an antioxidant moiety. These antioxidant polymers have greater bulk antioxidative properties than previously known. | 2008-12-18 |
| 20080311066 | Cosmetics Compositions Comprising at Least One Surfactant and at Least One Novel Ethylene Copolymer with Polyethylene Glycol Grafts - The invention relates to cosmetic compositions comprising:
| 2008-12-18 |
| 20080311067 | Hair conditioning compositions - The invention provides a hair conditioning composition comprising an aqueous carrier, a lamellar gel phase formed from cationic surfactant and fatty material and a rheology modifier for the lamellar gel phase which comprises a fatty acid and a water-soluble, nonionic polymer of alkylene oxide of the general formula: | 2008-12-18 |
| 20080311068 | HAIR CONDITIONING COMPOSITION COMPRISING AMINE-TYPE CATIONIC SURFACTANT AND DIRECT DYE - Disclosed is a hair conditioning composition comprising by weight: (a) from about 0.2% to about 10% of a cationic surfactant which is a salt of: (i) primary, secondary, and tertiary amines wherein the amines have one long alkyl or alkenyl group of from about 20 to about 24 carbon atoms; and (ii) acids such as 1-glutamic acid and lactic acid; (b) from about 1% to about 15% of a high melting point fatty compound; (c) from about 0.00005% to about 0.5% of a direct dye; and (d) an aqueous carrier. The composition of the present invention provide coloring benefits especially color enhancing and/or preventing color fade of colored hair, while providing improved conditioning benefits. | 2008-12-18 |
| 20080311069 | MALODOR COUNTERACTING COMPOSITIONS AND METHOD FOR THEIR USE - The present invention relates to the field of perfumery and more particularly to the field of malodor counteractancy. In particular, it relates to a malodor counteracting (MOC) compositions capable of neutralizing in an efficient manner, through chemical reactions, malodors of a large variety of origins and which can be encountered in the air, on textiles, bathroom or kitchen surfaces, and the like. The composition may be applied as is or in the form of a perfuming composition or in a consumer product or article containing the compound or perfume composition. | 2008-12-18 |
| 20080311070 | OPHTHALMIC COMPOSITION WITH HYALURONIC ACID - An ophthalmic composition comprising a polymeric biguanide composition having less than 18 mol % of terminal amine groups and 55 mol % or greater of terminal guanidine groups as measured by | 2008-12-18 |
| 20080311071 | Film Forming Compositon - The present application relates to a film forming composition for application to mammalian skin, which composition comprises at least one polyurethane based polymer together with at least one acrylate based polymer. The film forming composition provides effective skin coating with good adhesion to the skin, and may be used as a skin protector or a wound dressing. | 2008-12-18 |
| 20080311072 | Preparation of Soluble and Colloidal Molecularly Imprinted Polymers by Living Polymerization - The present invention describes a method for synthesis of relatively low molecular weight imprinted polymers using living polymerization, and their application in analytical chemistry, pharmacology, medicine and the food industry. Specifically the low-molecular weight polymers are synthesized by the polymerization of functional monomers in the presence of a template, such as a biological receptor, enzyme, nucleic acid, cell, virus, microorganism, tissue sample or drug using living initiator. The conditions of living polymerization ensure a relatively small size of synthesized molecules. Synthesized in this way molecules (dimers, oligomers, polymers, or their mixture) have a higher affinity to the template than the original monomers and can rebind it in vitro and/or in vivo. As a further aspect of the present invention, polymers synthesized as described above can be used as drugs in pharmacology and medicine, as receptor-specific ligands in analytical chemistry (sensors, assays), and for separations in the biotechnology, pharmaceutical and food industries. | 2008-12-18 |
| 20080311073 | Ilt3 Polypeptides and Uses Thereof - This invention provides a first polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water-soluble and does not comprise the Fc portion of an immunoglobulin. This invention also provides a second polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) the Fc portion of an immunoglobulin, wherein the Fc portion of the immunoglobulin comprises a function-enhancing mutation, and wherein the polypeptide is water-soluble. This invention further provides a third polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) a transmembrane domain. This invention further provides related nucleic acids, expression vectors, host vector systems, compositions, and articles of manufacture and therapeutic and prophylactic methods using the polypeptides of the invention. | 2008-12-18 |
| 20080311074 | Inhibitors against activation of NF-kappaB - A method of inhibiting NF-κB activation in a mammal including a human, which comprises the step of administering an effective dose of a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: | 2008-12-18 |
| 20080311075 | Hepatitis C Virus Inhibitors - The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. | 2008-12-18 |
| 20080311076 | Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents - Compounds of formula (Ia) are found to be active in inhibiting replication of flaviviridae viruses, wherein R | 2008-12-18 |
| 20080311077 | Antiviral Compounds - The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 2008-12-18 |
| 20080311078 | Self-Buffering Protein Formulations - The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use. The invention in these and other respects can be productively applied to a wide variety of proteins and is particularly useful for making and using self-buffering formulations of pharmaceutical proteins for veterinary and medical use, especially, in particular, for the treatment of diseases in human subjects. | 2008-12-18 |
| 20080311079 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease - The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds. | 2008-12-18 |
| 20080311080 | BIFIDOBACTERIUM IN THE TREATMENT OF INFLAMMATORY DISEASE - A strain of | 2008-12-18 |
| 20080311081 | Bacteria mediated gene silencing - Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium or BTP. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating viral diseases and disorders. The bacterium or BTP includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells. | 2008-12-18 |
| 20080311082 | Process for Treating Animal Waste - The present invention is directed to a process for reducing a population of one, or more than one target pathogen present in animal waste, including livestock manure , comprising administering one, or more than one protected bacteriophage strain to livestock. The one, or more than one bateriophage strain is capable of adsorbing to and killing the target pathogen, is released in vivo, and acts to clear the one or more than one pathogen from livestock gut and waste. The one, or more than one bacteriophage it further reduces the population of the one or more than one target pathogen in the waste or manure. The present invention also relates to a process for reducing a population of one, or more than one target pathogen present in liquid manure comprising treating the animal waste such as liquid manure with one, or more than one protected bateriophage strain, or phage components, or a combination thereof. | 2008-12-18 |
| 20080311083 | Methods of Modulating Beta Cell Function - Methods of modulating pancreatic function by modulating MCH signaling in a β cell. | 2008-12-18 |
| 20080311084 | Mapc Engraftment in the Hematopoietic System - The present invention relates to MAPCs and progeny derived therefrom to provide lymphohematopoietic cells in a tissue of the lymphohematopoietic system of a subject. | 2008-12-18 |
| 20080311085 | Method for treating an animal having damaged tissue structure - A method for treating an animal having damaged tissue structure includes harvesting a tissue sample from a subject harvesting a tissue sample from the animal, growing tendon-like cells from the tissue sample, and transplanting the tendon-like cells into the damaged tissue structure. Growing the tendon-like cells from the tissue sample can be accomplished by breaking the tissue sample into fragments, placing the fragments into a culture vessel, inducing at least some of the fragments to adhere to the culture vessel, and supplying the fragments with nutrients so that tendon-like cells contained therein divide and grow. | 2008-12-18 |
| 20080311086 | Use of Keratinocyte Composition for the Treatment of Restenosis - Methods for treating and/or preventing restenosis in a subject by local administration to the subject of a composition that includes keratinocytes is disclosed. Administration is preferably by way of a catheter having an inflatable balloon, such as a double or dumbbell-shaped balloon. | 2008-12-18 |
| 20080311087 | Human Umbilical Tissue-Derived Cell Compositions for the Treatment of Incontinence - Compositions for the treatment of incontinence are disclosed. More particularly, compositions of human umbilical tissue-derived cells and a carrier are disclosed. The compositions are useful in the treatment urinary and fecal incontinence. | 2008-12-18 |
| 20080311088 | Method of Treating Lung Diseases Using Cells Separated Or Proliferated From Umbilical Cord Blood - There is provided a method of treating lung diseases including administering cells separated or proliferated from umbilical cord blood to a patient suffering from such diseases. | 2008-12-18 |
| 20080311089 | Augmentation and Repair of Vocal Cord Tissue Defects - The present invention provides a method for corrective surgery in a human subject of a vocal cord defect being amenable to rectification by the augmentation of tissue subjacent to the vocal cord defect comprising the steps of:
| 2008-12-18 |
| 20080311090 | Methods for inhibition of proliferative disease, including hepatocellular carcinoma - The present invention is related to a method for modulating expression of protein kinase C-alpha associated with proliferative diseases. The invention further relates to a screening method utilizing the association between transcription factors (MZF-1 and Elk-1) and their DNA binding element (PKC-.alpha. promoter) to identify novel anticancer agents. | 2008-12-18 |
| 20080311091 | Engineered Dopamine Neurons and Uses Thereof - The invention relates to dopamine neuron determinants, the use of these determinants in differentiating cells to dopamine neurons, cells produced by the over-expression of these determinants, and uses of these cells. | 2008-12-18 |
| 20080311092 | Murine Stem Cells and Applications Thereof - The invention relates to animal solid tumour models which comprise a transgenic non-human mammal containing in its genome a DNA construct that comprises a gene created and/or activated by a genetic anomaly associated with human cancer operatively bound to a promoter that directs the expression of the gene in Sca1+ cells. The invention also relates to stem cells capable of specifically expressing in stem cells human genetic anomalies associated with human pathologies. Applications of these models and stem cells, such as diagnostic, therapeutic and prophylactic applications for human diseases, and products and methods are provided. | 2008-12-18 |
| 20080311093 | STEM CELL SECRETIONS AND RELATED METHODS - Stem cell secretions are derived from epithelial cells conditioned media. The stem cell secretions are then applied topically, orally, or rectally, etc., to derive health benefits from the growth factors and other molecules comprising the stem cell secretion. The stem cell secretion may optionally be modified by covalently bonding fatty acids to protect the molecules through the delivery process and to make them more readily available to cells. | 2008-12-18 |
| 20080311094 | Isolated Liver Stem Cells - Isolated liver progenitor stem cells and cell populations of isolated liver progenitor stem cells are disclosed. The progenitor stem cells originate from adult liver, especially human adult liver. The isolated progenitor stem cells have uses in medicine, hepatology, inborn errors of liver metabolism transplantation, infectious diseases and liver failure. Methods of isolating these cells and their culture is described. The isolated cells are characterized before and after differentiation. Their use for transplantation and as animal models of human disease, toxicology and pharmacology is disclosed. | 2008-12-18 |
| 20080311095 | Methods and compositions for increased transgene expression - Described herein are methods of expressing nucleic acids in T cells pre-exposed to a co-stimulatory signal and then transduced with adenoviral vectors. In some embodiments, the co-stimulation is provided by anti-CD3 and anti-CD28 antibodies and the adenoviral vector is pseudotyped for T-cell entry. The invention also relates to compositions for carrying out these methods, provided as kits or pharmaceutical compositions that can be used to treat diseases including immunological conditions and hematological malignancies. | 2008-12-18 |
| 20080311096 | Combinations of Cry1Ab and Cry1Fa as an insect resistance management tool - Compositions for controlling lepidopteran insects use Cry1Fa and Cry1Ab core toxin containing proteins in combination to delay or prevent development of resistance. | 2008-12-18 |
| 20080311097 | Treatment of Ibd and Ibs Using Both Probiotic Bacteria and Fermented Cereal as Treatment Effectors - The invention covers a novel treatment strategy that considerably improves conventional probiotic treatments of inflammatory bowel diseases, irritable bowel syndrome and other gastrointestinal disorders. Both probiotic microorganisms and the carrier of the probiotic microorganisms in form of a fermented cereal gruel are used as treatment effectors. Phospholipids may also be an effecter. The novel treatment strategy is capable of removing the symptoms of inflammatory bowel diseases regardless of a mild, moderate or severe stage of the disease. | 2008-12-18 |
| 20080311098 | COMPOUNDS AND METHODS FOR MODULATING THE IMMUNE RESPONSE AGAINST ANTIGENS - Chimeric nucleic acids and polypeptides comprising an antigen or an epitope thereof are described, as well as compositions and methods to increase the presentation of an antigen or epitope by MHC class II molecules and to modulate the immune response. | 2008-12-18 |
| 20080311099 | Pyridoxal-5-Phosphate and Related Compounds in Combination With Therapeutic Cardiovascular Compounds for Treating Angina - Methods for treating angina are described. A method for treating angina includes concurrently administering a compound with a therapeutic cardiovascular compound. A combination therapy employs suitable therapeutic cardiovascular compounds, such as a calcium channel blocker, a β-adrenergic blocker, nitrates, partial fatty acid oxidation inhibitors, potassium channel activators, or a mixture thereof, in combination with a compound such as pyridoxal-5′phosphate, pyridoxic acid, pyridoxal, pyridoxamine, 3-acylated analogues of pyridoxal, 3-acylated analogues of pyridoxal-4,5-aminal, pyridoxine phosphonate analogues, a pharmaceutically acceptable acid addition salt thereof, or a mixture thereof. The invention also includes a novel composition comprising at least one compound and nitrates, partial fatty acid oxidation inhibitors, potassium channel activators, calcium channel blockers, β-adrenergic blockers, or a mixture thereof. | 2008-12-18 |
| 20080311100 | Treatment of Keratinous Dryness With Glycerides - The present invention provides the use of medium chain glyceride(s) as an active ingredient for the preparation of a composition for oral and/or parenteral absorption and intended to prevent and/or treat dry and/or delicate keratinous substances. | 2008-12-18 |
| 20080311101 | Method to Reduce Oxalate Concentration by Administration of Oxalate Oxidase Crystals - The invention relates to methods to prevent, treat, or slow the progression of a disorder associated with elevated oxalate concentration, the method comprising administering oxalate oxidase crystals, cross-linked crystals, or compositions containing those crystals to an individual. Oxalate oxidase crystals and compositions for administration to an individual are also provided, including stabilized crystals, such as cross-linked crystals of oxalate oxidase. | 2008-12-18 |
| 20080311102 | Acylglycerol Acyltransferase-Like Protein Mgat-X1 and Uses Thereof - The present invention is directed to a polynucleotide sequence of a novel acylglycerol acyltransferase-like protein MGAT-X1. The invention also provides the human MGAT-X1 associated with the dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases. The invention also provides assays for the identification of compounds useful for the modulation of dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases for treating of such diseases associated with expression of the MGAT-X1. The invention also features compounds which bind to and/or activate or inhibit the activity of MGAT-X1 as well as pharmaceutical compositions comprising such compounds. | 2008-12-18 |
| 20080311103 | Anti-Inflammatory Peptides and Methods of Use Thereof - Anti-inflammatory peptides derived from naturally occurring digests of proteins including apolipoprotein A-I, apolipoprotein A-II, fibrinogen γ chain, fibrinogen Aa, low-density lipoprotein receptor, ADAM 8, cadherin 4, and calcitonin receptor are provided, along with pharmaceutical compositions comprising same and methods of treating inflammatory diseases using same. | 2008-12-18 |
| 20080311104 | STABILIZED THROMBIN COMPOSITIONS - Stabilized thrombin compositions, processes for preparing them, and kits comprising them are disclosed. The compositions comprise thrombin, a bacteriostatically effective amount of benzyl alcohol or chlorobutanol, and 0.10%-5.0% (w/v) sucrose in aqueous solution. The compositions are stable when stored at 2° C.-8° C. for four weeks or more. | 2008-12-18 |
| 20080311105 | Reversibly Inactivated Acidified Plasmin - The present invention provides a fibrinolytic composition useful as a therapeutic for administration to a patient having a thrombotic occlusion. In one aspect of the present invention, the fibrinolytic composition comprises a reversibly inactivated acidified serine protease substantially free of a plasminogen activator, a low buffering capacity buffer, and optionally, a stabilizing agent. In another aspect of the invention, the fibrinolytic composition of the present invention comprises a reversibly inactivated acidified plasmin substantially free of a plasminogen activator, a low buffering capacity buffer, and optionally, a stabilizing agent. | 2008-12-18 |
| 20080311106 | Product Comprising a C4bp Core Protein and a monomeric Antigen, and Its Use - The invention provides a product which comprises a C4bp core protein and a monomeric antigen, desirably in the form of a fusion protein. Monomeric antigens include malarial and influenza antigens. The C4bp core protein provides for assembly of multimeric complexes of the monomeric antigen, or mixtures thereof. The complexes are useful as vaccines. | 2008-12-18 |
| 20080311107 | Novel Gene Disruptions, Compositions and Methods Relating Thereto - The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO188, PRO235, PRO266, PRO337, PRO361, PRO539, PRO698, PRO717, PRO846, PRO874, PRO98346, PRO1082, PRO1097, PRO1192, PRO1268, PRO1278, PRO1303, PRO1308, PRO1338, PRO1378, PRO1415, PRO1867, PRO1890, PRO3438, PRO19835, PRO36915, PRO36029, PRO4999, PRO5778, PRO5997, PRO6079, PRO6090, PRO7178, PRO21184, PRO7434, PRO9822, PRO9833, PRO9836, PRO9854, PRO9862, PRO10284, PRO37510, PRO35444, PRO20473, PRO21054 or PRO35246 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities. | 2008-12-18 |
| 20080311108 | Polypeptides - The invention relates to antigenic polypeptides expressed by pathogenic microbes, vaccines comprising said polypeptides; therapeutic antibodies directed to said polypeptides and methods to manufacture said polypeptides, vaccines and antibodies. | 2008-12-18 |
| 20080311109 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF BREAST CANCER - Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer. | 2008-12-18 |
| 20080311110 | Chimeric Vaccine for Haemophilus Influenzae-Induced Disease - The invention described herein relates to a chimeric protein comprising the NTHi twitching pilus major subunit protein (PilA) presenting a portion of the NTHi OMP P5 protein. The invention provides for vaccine compositions comprising the recombinant chimeric protein and methods of eliciting an immune response using the recombinant chimeric proteins of the invention. | 2008-12-18 |
| 20080311111 | Competitive Domain Antibody Formats That Bind Interleukin 1 Receptor Type 1 - The invention relates to dAb monomers that bind IL-1R1 and inhibit binding of IL-1 (e.g., IL-1α and/or IL-1β) and IL-1ra to IL-1R1, and to ligands comprising such dAb monomers. The invention relates to protease resist and dAb monomers, and to ligands comprising protease resistant dAb monomers. The invention also relates to nucleic acids including vectors that encode the dAb monomers and ligand, to host cells that comprise the nucleic acids and to method for producing a dAb monomer or ligand. The invention also relates to pharmaceutical compositions that comprise the dAb monomers or ligands, and to therapeutic methods that comprise administering a dAb monomer of ligand. | 2008-12-18 |
| 20080311112 | USE OF TOLL-LIKE RECEPTOR-9 AGONISTS, TOLL-LIKE RECEPTOR-4 ANTAGONISTS, AND/OR NUCLEAR OLIGOMERIZATION DOMAIN-2 AGONISTS FOR THE TREATMENT OR PREVENTION OF TOLL-LIKE RECEPTOR-4-ASSOCIATED DISORDERS - The present invention relates to the use of a TLR9 agonist and/or a TLR4 antagonist and/or a NOD2 agonist for treatment or prevention of disorders involving TLR4 activation, such as systemic sepsis and necrotizing enterocolitis. | 2008-12-18 |
| 20080311113 | METHOD FOR TREATING ADAMTS-5-ASSOCIATED DISEASE - The present invention relates to methods of treating ADAMTS-5-associated diseases and particularly osteoarthritis comprising administering an agent capable of modulating ADMATS-5 activity to a subject afflicted with the disease. The agent is preferably a biaryl sulfonamide compound. The invention is based, in part, on the discovery that transgenic animals that do not express functional ADAMTS-5 show a reduction in the degree of osteoarthritis after the induction of osteoarthritis as compared to WT animals. Furthermore, the ADAMTS-5 transgenic animals have reduced aggrecanase activity in articular tissue as compared to WT animals. These animals are good models for ADAMTS-5-associated diseases, and for screening of drugs useful in the treatment and/or prevention of these diseases. There are no other animal models in which the deletion of the activity of a single gene is capable of abrogating the course of osteoarthritis. Accordingly, these animals also show that osteoarthritis can be prevented and/or treated by administering to a subject an ADAMTS-5 inhibitory agent and particularly an agent capable of inhibiting the aggrecanase activity of ADAMTS-5. | 2008-12-18 |
| 20080311114 | USE OF MORPHOGENIC PROTEINS TO TREAT HUMAN DISC DISEASE - Bone morphogenetic proteins (BMPs) are introduced into an affected intervertebral disc without the inclusion of disc cells. The inventions applies to all known and yet-to-be developed or discovered BMPs, including BMP-1, -2, -3, -4, -5, -6, -7, -8, -9, -10, . . . BMPn. The BMP(s) may be obtained from natural and/or recombinant sources. The BMP(s) may be introduced using any surgical technique, including percutaneous or laparoscopic approaches. As one delivery mechanism, a passageway may be formed through the annulus, with the substances then being introduced through the passageway. Alternatively, a carrier may be sewn or otherwise adhered to the inside or outside of the existing annulus using standard surgical procedures. Additional therapeutic substances such as culture medium, growth factors, differentiation factors, hydrogels, polymers, antibiotics, anti-inflammatory medications, or immunosuppressive medications could be introduced in conjunction with the BMP(s). | 2008-12-18 |
| 20080311115 | ANTI-IL-20 ANTIBODY AND ITS USE IN TREATING IL-20 ASSOCIATED INFLAMMATORY DISEASES - This invention features an antibody specifically binding to human IL-20 (e.g., mAb 7E and a equivalent thereof) and its use in treating an IL-20 associated inflammatory disease, such as atherosclerosis, RA, psoriasis, psoriatic arthritis, bacteria-induced gastric ulcer, and acute renal failure. | 2008-12-18 |
| 20080311116 | Process for the Determination of Inflammatory Process and Pharmaceutical Compositions for the Treatment Thereof - A method for analyzing extracellular body fluids as to the presence of the Y-box protein YB-1 and fragments thereof, which are secreted by the cell, in order to determine inflammatory processes and malignant diseases in mammals. Also, it relates to the use of YB-1 as a marker and a kit for detecting YB-1, polypeptide fragments of YB-1, and combinations thereof. Also disclosed is a pharmaceutical composition which is used for treating inflammatory processes and malignant diseases and which contains the YB-1 protein, fragments of protein YB-1, and antibodies against the YB-1 protein and/or fragments of protein YB-1. | 2008-12-18 |
| 20080311117 | Antibodies against PD-1 and uses therefor - This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders. | 2008-12-18 |
| 20080311118 | VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS AND USES THEREOF - The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and stroke using VEGF antagonists are also provided. | 2008-12-18 |
| 20080311119 | ANTIBODY FORMULATIONS - Formulations of VLA-4 binding antibody are described. | 2008-12-18 |
| 20080311120 | AUTOCRINE GROWTH FACTOR RECEPTOR ANTIBODIES AND METHODS - Disclosed herein are antitumor compositions and methods of interfering with the biological activity of PC cell derived growth factor (PCDGF), anti-PCDGF receptor antibodies, fragments thereof, and methods of making anti-PCDGF receptor antibodies. The methods involve inhibiting the proliferation of tumor cells expressing the PCDGF receptor by contacting the surface of the cell with anti-PCDGF receptor antibodies. Anti-PCDGF receptor antibodies are capable of binding to the surface of a cell and interfering with the binding of PCDGF to its receptor. Also provided are compositions comprising anti-PCDGF receptor antibodies and cytotoxic molecules (e.g., toxins, oncotoxins, mitotoxins, immunotoxins, and antisense oligonucleotides). | 2008-12-18 |
| 20080311121 | ANTIBODY ANTAGONISTS OF VE-CADHERIN WITHOUT ADVERSE EFFECTS ON VASCULAR PERMEABILITY - The murine epitope sequence recognized by antibody E4B9 shares 100% homology with human VE-cadherin, so this antibody was examined to determine if it cross-reacts with human VE-cadherin. Western-blot analysis of several VE-cadherin expressing human and murine cells indicated that E4B9 indeed cross-reacts with human VE-cadherin. ( | 2008-12-18 |
| 20080311122 | Antagonists of Hmgb1 and/or Rage and Methods of Use Thereof - Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn s disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, lupus, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies. | 2008-12-18 |
| 20080311123 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF BREAST CANCER - Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer. | 2008-12-18 |
| 20080311124 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF BREAST CANCER - Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer. | 2008-12-18 |
| 20080311125 | Scytovirin Domain 1 Related Polypeptides - A scytovirin domain 1 (SD1) polypeptide, a nucleic acid encoding the polypeptide, and related fusion proteins, conjugates, isolated cells, vectors, and antibodies, as well as a method of inhibiting a viral infection using the same. | 2008-12-18 |
| 20080311126 | Antisense Oligonucleotides Directed to Ribonucleotide Reducatase R2 and Uses Thereof in Combination Therapies for the Treatment of Cancer - Combination products comprising an antisense oligonucleotide against the gene encoding a mammalian ribonucleotide reductase R2 protein and one or more immunotherapeutic agents, such as cytokines, non-cytokine adjuvants, monoclonal antibodies and cancer vaccines. The combinations can further comprise one or more chemotherapeutic agents. Methods of treating cancer in a mammal using the combinations are also provided. | 2008-12-18 |
| 20080311127 | Combination therapy for treating disease - Disclosed are methods for treating cancer comprising administering a xenotypic antibody and a chemotherapeutic drug to a patient suffering from cancer. Also disclosed is a method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor antigen present in the host serum, which antigen does not elicit an effective host immune response, comprising administering to the patient a chemotherapeutic drug and a composition comprising a binding agent that specifically binds to a first epitope on the antigen and allowing the binding agent to form a binding agent/antigen pair, wherein an effective host immune response is elicited against a second epitope on the antigen. | 2008-12-18 |
| 20080311128 | Method for Treating Pathological Pulmonary Conditions and Bleomycin Associated Pulmonary Fibrosis - Methods for treating pathological pulmonary conditions and bleomycin associated pulmonary fibrosis administer IL-16 antagonists, for example, anti-IL-16 antibodies, to subjects. | 2008-12-18 |
| 20080311129 | ADHERENCE INHIBITOR DIRECTED TO AND METHOD OF MAKING AND USING - A method for the production of antibodies or microbial adherents administers is disclosed. The antibodies or microbial adherents inhibitors are administered to a patient suffering from strep throat to substantially prevent the adherents of colony-forming immunogens or haptens in the throat of the patient. Application of the antibodies should decrease the colonization of the oropharnyx, and therefore decrease symptoms of the sore inflamed throat and ultimately decrease the need for antibiotics. | 2008-12-18 |
| 20080311130 | Integrin Alpha L I Domain Mutants with Increased Binding Affinity - The present invention provides an isolated polypeptide capable of binding to | 2008-12-18 |
| 20080311131 | Human Mob-5 (IL-24) receptors and uses thereof - The present invention provides the receptors for Mob-5 (IL-24). One of the Mob-5 receptors comprises IL-22R1 and IL-20R2. Another Mob-5 receptor comprises IL-20R1 and IL-22R2. The invention also provides methods of inhibiting the Mob-5 receptor as well as methods of detecting cancer by detecting the presence of the Mob-5 receptor. | 2008-12-18 |
| 20080311132 | Human Complement C3 Derivates with Cobra Venom Factor-Like Function - A modified human complement C3 protein (C3) is disclosed comprising a substitution of a portion of a human C3 protein, with a corresponding portion of a Cobra Venom Factor protein (CVF) which results in a human C3 protein with CVF functions, but with substantially reduced immunogenicity. Advantageously, the C3 protein can be manipulated to contain at least one of the following CVF functions: increased stability of the C3 convertase and increased resistance to the actions of factors H and/or I. A large number of hybrid C3 proteins containing substitutions in the C-terminal portion of the alpha chain of C3 are presented and tested for the above functions. Methods of treatment of diseases such as reperfusion injury, autoimmune diseases, and other diseases of increased complement activation are presented as well as methods of increasing the effectiveness of gene therapeutics and other therapeutics. | 2008-12-18 |
| 20080311133 | METHODS OF USING MULTIVALENT MHC CLASS II-PEPTIDE CHIMERAS - The present invention provides a multimeric complex of at least two chimeric molecules, wherein the chimeric molecules comprise an immunoglobulin constant region element and two MHC elements wherein each MHC element is associated with a peptide, and wherein the chimeric molecules are covalently linked through a carbohydrate residue of the immunoglobulin constant region element by a polyalkylene glycol linker. Methods of making and using the multimeric complexes are also provided. | 2008-12-18 |
| 20080311134 | CYSTEINE ENGINEERED ANTI-MUC16 ANTIBODIES AND ANTIBODY DRUG CONJUGATES - Cysteine engineered anti-MUC16 antibodies are engineered by replacing one or more amino acids of a parent anti-MUC16 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-MUC16 antibodies are provided. Cysteine engineered anti-MUC16 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-MUC16 antibody-drug conjugates having Formula I: | 2008-12-18 |
| 20080311135 | IMMUNE COMPLEX VACCINATION AS A STRATEGY TO ENHANCE IMMUNITY IN THE ELDERLY AND OTHER IMMUNE COMPROMISED POPULATIONS - The present invention generally concerns methods and compositions for improving the immune system of an individual that is an immune-compromised individual. In particular aspects, the immune-compromised individual is elderly or is immunosuppressed, such as from chemotherapy or immunosuppressants following organ or tissue transplantation. In specific embodiments, the invention relates to delivery to the immune-compromised individual of immune complexes harboring an antigen and an antibody that immunologically recognizes the antigen. The antigen may be viral, bacterial, or fungal, for example. | 2008-12-18 |
| 20080311136 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation - This invention relates to compounds comprising one or more therapeutic and/or diagnostic moieties and one or more functional moieties linked together via one or more triazole-containing linkers and to their intermediates and methods of their preparation. The triazole-containing linker may optionally contain one or more conditionally-cleavable or conditionally-transformable moieties and one or more spacer systems in between said moiety/moieties and the one or more therapeutic and/or diagnostic moieties. | 2008-12-18 |
| 20080311137 | Carcinoembryonic Antigen Fusions and Uses Thereof - Polynucleotides encoding carcinoembryonic antigen (CEA) fusion proteins are provided, the CEA fusion proteins comprising a CEA protein, or functional variant thereof, fused to a substantial portion of an immunoenhancing element. The polynucleotides of the present invention can elicit an immune response in a mammal, which, in preferred embodiments, is stronger than the immune response elicited by a wild-type CEA. The gene encoding CEA is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the CEA tumor-associated antigen, wherein aberrant CEA expression is associated with a carcinoma or its development. This invention specifically provides adenoviral vector and plasmid constructs carrying polynucleotides encoding CEA fusion proteins and discloses their use in vaccines and pharmaceutical compositions for preventing and treating cancer. | 2008-12-18 |
| 20080311138 | Adjuvant Activity of Gastrointestinal Peptides - Gastrointestinal peptides (GPs) have been found to function as vaccine adjuvants, and in particular as mucosal adjuvants. The invention provides an immunogenic composition comprising: (a) a GP adjuvant; and (b) an antigen. The composition is preferably suitable for mucosal administration e.g. intranasal administration. | 2008-12-18 |
| 20080311139 | Plant Produced Vaccine for Amebiasis - Disclosed herein are methods of making a vaccine against | 2008-12-18 |
| 20080311140 | Antigen specific immunosuppression by dendritic cell therapy - The invention includes genetically modified dendritic cells expressing at least two immunosuppressive molecules. The genetically modified dendritic cells have the ability to induce tolerance. Enhanced tolerogenicity is useful for prolonging survival of a foreign transplant and for treatment of autoimmune diseases. | 2008-12-18 |
| 20080311141 | CANCER VACCINES AND VACCINATION METHODS - Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein. | 2008-12-18 |
| 20080311142 | CANCER VACCINES AND VACCINATION METHODS - Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein. | 2008-12-18 |
| 20080311143 | CONSTRUCTION OF CHIMERA PRRSV, COMPOSITIONS AND VACCINE PREPARATIONS - Chimeric replicons of North American Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) containing the 5′ sequence of an avirulent strain of PRRSV and a 3′ sequence of a virulent strain of PRRSV are provided. Further provided is a method of producing attenuated PRRSV from the chimeric replicon. Also provided are compositions containing the replicon or attenuated virus. Vaccines and a method of vaccinating pigs against PRRSV are also provided. | 2008-12-18 |
| 20080311144 | MUTANT FORMS OF CHOLERA HOLOTOXIN AS AN ADJUVANT - Mutant cholera holotoxins having single or double amino acid substitutions or insertions have reduced toxicity compared to the wild-type cholera holotoxin. The mutant cholera holotoxins are useful as adjuvants in antigenic compositions to enhance the immune response in a vertebrate host to a selected antigen from a pathogenic bacterium, virus, fungus, or parasite, a cancer cell, a tumor cell, an allergen, or a self-molecule. | 2008-12-18 |
| 20080311145 | PROTEIN CAGE IMMUNOTHERAPEUTICS - The present invention provides compositions of heat shock protein cages for use in therapeutic vaccines. The heat shock protein cages of the invention have attached antigen, located either on the interior or exterior of the protein cage, and optionally an adjuvant. | 2008-12-18 |
| 20080311146 | Immunogenic Composition - The present invention discloses an immunogenic composition comprising at least two different isolated staphylococcal polypeptides, each comprising an IgG binding domain. In a further embodiment, the invention discloses a polypeptide comprising: a protein A part including at least one IgG binding domain and an Sbi part including at least one IgG binding domain. | 2008-12-18 |
| 20080311147 | Rhabdoviral N-Fusion Proteins as Carrier for Foreign Antigens - Rabies virus (RV) nucleoprotein (N) tightly encapsidates the genomic and antigenomic RNA thereby forming the ribonucleoprotein (RNP) complex. Antigens presented in a rigid and repetitive organization are sufficient to activate B cells to proliferate. In addition to the repetitive organization, it has been shown that RV N protein induces potent T-helper responses resulting in long-lasting and strong humoral immune responses against RV. The possibility to directly manipulate the genome of RV allows us to examine whether the immunogenicity of foreign antigens can be enhanced via incorporation into the RNP structure. A recombinant RV expressing an RV N-green fluorescent protein (GFP) fusion protein. The chimeric N-GFP fusion protein was efficiently expressed and incorporated into RV RNP and virions. Moreover, the recombinant RNP induces a strong humoral immune response against GFP in mice. In contrast, mice inoculated with GFP alone or a combination of wild-type RV RNPs and GFP did not trigger any GFP-specific humoral responses using the same immunization schedule. These results indicate the usefulness of RV-based vectors as killed vaccines against other infectious diseases. | 2008-12-18 |
| 20080311148 | DNA-transfection system for the generation of infectious influenza virus - The present invention is based on the development of a dual promoter system (preferably a RNA pol I-pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome. The viral product of the system is produced when the plasmids of the system are introduced into a suitable host cell. One application of the system is production of attenuated, reassortant influenza viruses for use as antigens in vaccines. The reassortant viruses generated by cotransfection of plasmids may comprise genes encoding the surface glycoproteins hemagglutinin and neuraminidase from an influenza virus currently infecting the population and the internal genes from an attenuated influenza virus. An advantageous property of the present invention is its versatility; the system may be quickly and easily adapted to synthesize an attenuated version of any RNA virus. Attenuated or inactivated RNA viruses produced by the present invention may be administered to a patient in need of vaccination by any of several routes including intranasally or intramuscularly. | 2008-12-18 |
| 20080311149 | DNA-transfection system for the generation of infectious influenza virus - The present invention is based on the development of a dual promoter system (preferably a RNA pol I-pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome. The viral product of the system is produced when the plasmids of the system are introduced into a suitable host cell. One application of the system is production of attenuated, reassortant influenza viruses for use as antigens in vaccines. The reassortant viruses generated by cotransfection of plasmids may comprise genes encoding the surface glycoproteins hemagglutinin and neuraminidase from an influenza virus currently infecting the population and the internal genes from an attenuated influenza virus. An advantageous property of the present invention is its versatility; the system may be quickly and easily adapted to synthesize an attenuated version of any RNA virus. Attenuated or inactivated RNA viruses produced by the present invention may be administered to a patient in need of vaccination by any of several routes including intranasally or intramuscularly. | 2008-12-18 |
| 20080311150 | Novel sequences encoding hepatitis C virus glycoproteins - The present invention concerns a modified nucleic acid molecule comprising a nucleotide sequence coding for a full length hepatitis C virus (HCV) glycoprotein selected from the group consisting of E1 glycoprotein and E1/E2 glycoprotein heterodimer, this molecule having at least one nucleotide alteration, wherein, due to this alteration, at least one RNA splice site selected from the group consisting of RNA splice acceptor and RNA splice donor sites is eliminated from the coding sequence. The invention is also directed to methods for expressing on the surface of a cell and a pseudovirion an HCV glycoprotein, wherein the majority of the glycoprotein is full length. The invention further provides a cell and a pseudovirion expressing such glycoprotein. The invention still further provides a method for determining whether an agent inhibits HCV fusion with and entry into a target cell. The invention also provides an agent that inhibits HCV fusion with and entry into a target cell. The invention further provides methods for treating a subject afflicted with an HCV-associated disorder, for preventing an HCV infection in a subject, and for inhibiting in a subject the onset of an HCV-associated disorder. | 2008-12-18 |
| 20080311151 | Vaccine For Periodontal Disease - The present invention relates to novel bacterial isolates identified by their 16S rRNA DNA, that cause periodontal disease in companion animals, polynucleotide sequences contained therein, polypeptides encoded by such polynucleotide sequences and vaccines comprising such bacteria, polynucleotides, or polypeptides. Also provided are methods for treating and preventing periodontal disease and kits for detecting and treating periodontal disease kits for detecting and preventing periodontal disease. In addition, methods for assessing the efficacy of a vaccine against periodontal diseases in an animal are provided. | 2008-12-18 |
| 20080311152 | MODULATION OF DEVELOPMENTAL IMMUNE PROGRAMMING AND PROTECTION AGAINST CARDIOVASCULAR DISEASE, DIABETES, INFECTIOUS DISEASES, AND CANCER - Maternal adaptive immunity conveys temporary humoral immune protection to neonates. The disclosure demonstrates the influence of the in utero environment on adult atherosclerosis and provides evidence for persistent effects of maternal immunization on adult immune responses. The disclosure provides methods and compositions useful for immunization and more particularly for actively modulating the fetal programming of the immune system for the purpose of preventing or treating immune-modulated diseases. The disclosure also provides interventions to protect offspring and immunized subjects against insulin resistance. | 2008-12-18 |
| 20080311153 | ATTENUATED INFLUENZA VIRUS AND A LIVE VACCINE COMPRISING THE SAME - The present invention relates to an isolated attenuated influenza virus strain and a live vaccine comprising the same. The isolated attenuated influenza virus strain is prepared by cold-adaptation of a mother strain which carries 6 internal genomes of A/PR/8/34(H1N1) and two surface antigens HA and NA of A/Aichi/2/68(H3N2). The attenuated influenza virus strain and the live vaccine of the present invention are useful for prevention of seasonal influenza episodes and sudden outbreak of influenza pandemics of predicted or unknown identity, since they have safety, efficacy, high production yield, immediate protection against variety of influenza subtypes and prolonged protection against specific influenza subtype. | 2008-12-18 |
